MY117969A - Agent with an antidepressive effect comprising pramipexole and sertraline - Google Patents

Agent with an antidepressive effect comprising pramipexole and sertraline

Info

Publication number
MY117969A
MY117969A MYPI99002869A MYPI9902869A MY117969A MY 117969 A MY117969 A MY 117969A MY PI99002869 A MYPI99002869 A MY PI99002869A MY PI9902869 A MYPI9902869 A MY PI9902869A MY 117969 A MY117969 A MY 117969A
Authority
MY
Malaysia
Prior art keywords
pramipexole
sertraline
agent
antidepressive effect
antidepressive
Prior art date
Application number
MYPI99002869A
Other languages
English (en)
Inventor
Jerzy Prof Dr Maj
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY117969A publication Critical patent/MY117969A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI99002869A 1998-07-07 1999-07-07 Agent with an antidepressive effect comprising pramipexole and sertraline MY117969A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19830201A DE19830201A1 (de) 1998-07-07 1998-07-07 Mittel mit antidepressiver Wirkung

Publications (1)

Publication Number Publication Date
MY117969A true MY117969A (en) 2004-08-30

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99002869A MY117969A (en) 1998-07-07 1999-07-07 Agent with an antidepressive effect comprising pramipexole and sertraline

Country Status (32)

Country Link
US (1) US6255329B1 (https=)
EP (1) EP1093369B1 (https=)
JP (1) JP2002520273A (https=)
KR (1) KR100557692B1 (https=)
CN (1) CN1230168C (https=)
AR (1) AR019896A1 (https=)
AT (1) ATE228365T1 (https=)
AU (1) AU762128B2 (https=)
BG (1) BG64972B1 (https=)
BR (1) BR9911768A (https=)
CA (1) CA2336833C (https=)
CZ (1) CZ294087B6 (https=)
DE (2) DE19830201A1 (https=)
DK (1) DK1093369T3 (https=)
EA (1) EA003142B1 (https=)
EE (1) EE04296B1 (https=)
ES (1) ES2183583T3 (https=)
HU (1) HUP0103922A3 (https=)
ID (1) ID27776A (https=)
IL (1) IL140603A0 (https=)
MY (1) MY117969A (https=)
NO (1) NO20010064L (https=)
NZ (1) NZ509729A (https=)
PL (1) PL195043B1 (https=)
PT (1) PT1093369E (https=)
RS (1) RS49795B (https=)
SK (1) SK284923B6 (https=)
TR (1) TR200100146T2 (https=)
TW (1) TW592698B (https=)
WO (1) WO2000002542A2 (https=)
YU (1) YU401A (https=)
ZA (1) ZA200100090B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
WO2005070428A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (r)-프라미펙솔을 사용하는 조성물 및 방법
EP2341912B1 (en) 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
JP2012525426A (ja) * 2009-04-30 2012-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド うつ病を治療する方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
IL312486B2 (en) * 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN121221782A (zh) 2017-06-30 2025-12-30 傲拓神经科学公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
CN110028464B (zh) * 2019-04-26 2022-11-18 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
JP3947582B2 (ja) * 1995-08-15 2007-07-25 中外製薬株式会社 不安神経症治療剤
NZ325914A (en) * 1996-03-29 1999-09-29 Pfizer Benzyl(idene)-lactam derivatives and salts thereof, their preparation and their use as selective (ant)agonists of 5-ht1a and/or 5-ht1d receptors and thus are effective as psychotherapeutic agents
ATE282417T1 (de) * 1996-12-02 2004-12-15 Merck Sharp & Dohme Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders

Also Published As

Publication number Publication date
EA200100084A1 (ru) 2001-08-27
KR20010079491A (ko) 2001-08-22
IL140603A0 (en) 2002-02-10
BG64972B1 (bg) 2006-11-30
RS49795B (sr) 2008-06-05
BR9911768A (pt) 2001-04-03
EP1093369B1 (de) 2002-11-27
ID27776A (id) 2001-04-26
CA2336833A1 (en) 2000-01-20
PL345842A1 (en) 2002-01-14
CZ294087B6 (cs) 2004-10-13
HUP0103922A2 (hu) 2002-03-28
EA003142B1 (ru) 2003-02-27
EE200100014A (et) 2002-06-17
WO2000002542A3 (de) 2000-06-22
KR100557692B1 (ko) 2006-03-07
HUP0103922A3 (en) 2002-08-28
CN1230168C (zh) 2005-12-07
EE04296B1 (et) 2004-06-15
TR200100146T2 (tr) 2001-07-23
CZ200177A3 (en) 2001-06-13
SK284923B6 (sk) 2006-02-02
ZA200100090B (en) 2002-04-04
ATE228365T1 (de) 2002-12-15
WO2000002542A2 (de) 2000-01-20
AU5030399A (en) 2000-02-01
NZ509729A (en) 2003-06-30
NO20010064D0 (no) 2001-01-05
SK112001A3 (en) 2001-10-08
DE59903556D1 (de) 2003-01-09
DK1093369T3 (da) 2002-12-16
AU762128B2 (en) 2003-06-19
CN1308533A (zh) 2001-08-15
AR019896A1 (es) 2002-03-20
CA2336833C (en) 2008-09-23
BG105112A (bg) 2001-10-31
JP2002520273A (ja) 2002-07-09
PL195043B1 (pl) 2007-08-31
YU401A (sh) 2003-10-31
ES2183583T3 (es) 2003-03-16
PT1093369E (pt) 2003-03-31
TW592698B (en) 2004-06-21
US6255329B1 (en) 2001-07-03
EP1093369A2 (de) 2001-04-25
HK1037976A1 (en) 2002-03-01
NO20010064L (no) 2001-03-02
DE19830201A1 (de) 2000-01-13

Similar Documents

Publication Publication Date Title
MY117969A (en) Agent with an antidepressive effect comprising pramipexole and sertraline
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE60112055D1 (de) Inhibitoren von gamma-secretase
DE60002185D1 (de) Transplantation von hämatopoietischen zellen
ATE289781T1 (de) Schlinge mit polsterung zur behandlung von harninkontinenz
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
DE60117046D1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
GB0025173D0 (en) Therapeutic agents
NO20005290L (no) Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom
TR200003071T2 (tr) Sistein-proteazı önleyici etkiye sahip yeni heterosiklik ikame edilmiş amidler
ATE402149T1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
NO20054744L (no) Behandling av Alzheimers sykdom
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
IL143280A0 (en) Use of riluzole for treating acoustic traumas
BR0309110A (pt) composições e processo de tratamento da doença de alzheimer
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
ATE323486T1 (de) Verwendung des riluzols oder dessen salzen zur phophylaxe und behandlung der adrenoleukodystrophie